United States: High Court Rules Pharmaceutical Sales Reps Are Exempt From FLSA's Overtime Requirements

On June 18, 2012, with Justice Samuel Alito writing for a 5-4 majority, the U.S. Supreme Court considered whether the term "outside salesman," as defined by Department of Labor (DOL) regulations, encompasses pharmaceutical sales representatives. The Court ruled that these sales representatives qualify as outside salesmen and thus, are exempt from the overtime compensation requirements of the Fair Labor Standards Act (FLSA). Given "the industry's decades-long practice of classifying pharmaceutical detailers as exempt employees" and the DOL's failure to initiate any enforcement actions with respect to sales representatives, the Court found that a decision to the contrary "would result in precisely the kind of 'unfair surprise' against which our cases have long warned." Although a critical decision for the pharmaceutical industry in its own right, the case generally has been viewed more importantly for its insight as to the weight the Supreme Court would give to agency views of the laws they enforce. Christopher v. SmithKline Beecham Corp., DBA GlaxoSmithKline, No. 11–204, U.S. Supreme Court (June 18, 2012).

Factual Background

SmithKline Beecham Corporation develops, manufactures, and sells prescription drugs. Pharmaceutical companies, such as SmithKline, promote their drugs to physicians through a process called "detailing," whereby their employees ("detailers" or "pharmaceutical sales representatives") provide information to physicians about the company's products in hopes of persuading them to write prescriptions. These representatives' primary duty is to obtain nonbinding commitments from physicians to prescribe their employer's prescription drugs.

SmithKline pharmaceutical sale representatives spend approximately 40 hours each week calling on physicians to discuss benefits, features, and risks of certain drugs. Outside of normal business hours, the representatives spend an additional 10 to 20 hours each week attending events, reviewing product information, returning phone calls, responding to emails, and performing other miscellaneous tasks. SmithKline did not pay the representatives time-and-one-half wages when they worked in excess of 40 hours per week.

Several of SmithKline's pharmaceutical sales representatives brought suit against the company arguing that SmithKline violated the FLSA by failing to compensate them for overtime hours worked. The trial judge ruled in favor of SmithKline. The representatives filed a motion to alter or amend this judgment, contending that the trial judge had erred in failing to accord controlling deference to the DOL's interpretation of the pertinent regulations. The trial judge rejected this motion and the Ninth Circuit Court of Appeals affirmed, agreeing that the DOL's interpretation was not entitled to controlling deference. The case eventually reached the U.S. Supreme Court.

Legal Analysis

While the FLSA obligates employers to compensate employees for hours in excess of 40 per week at a rate of one-and-one-half times the employees' regular wages, it exempts workers "employed . . . in the capacity of outside salesman." Congress did not define the term "outside salesman," but it delegated authority to the DOL to issue regulations to define the term. Under what the Court called the DOL's "general" regulation (29 CFR §541.500) an outside salesman is any employee whose primary duty is making any sale, exchange, contract to sell, consignment for sale, shipment for sale, or other disposition.

The Court noted that the DOL first announced its view that pharmaceutical detailers are not exempt outside salesmen in an amicus brief filed in the Second Circuit in 2009. However, the agency changed and narrowed its views on what constitutes a "sale" for the purposes of the outside sales exemption. The DOL's new position is that "[a]n employee does not make a 'sale' for purposes of the 'outside salesman' exemption unless he actually transfers title to the property at issue." As such, the representatives argued that obtaining a nonbinding commitment to prescribe drugs does not constitute a sale. Both the representatives and the DOL argued that this interpretation is entitled to deference.

This new interpretation, the Court found, is "flatly inconsistent with the FLSA," which defines "sale" to mean a "consignment for sale" that does not involve the transfer of title. The Court concluded that the DOL's interpretation is neither entitled to deference "nor persuasive in its own right."

The Court noted that the definition of outside salesman in the DOL's regulation includes a "broad catchall phrase: 'other disposition'." This phrase, the Court concluded, "is most reasonably interpreted as including those arrangements that are tantamount, in a particular industry, to a paradigmatic sale of a commodity." Obtaining a nonbinding commitment from a physician to prescribe a drug, which was "the most that petitioners were able to do to ensure the eventual disposition" of SmithKline's products "comfortably falls within the catch-all category of 'other disposition'." Based on this interpretation, the Court ruled that the SmithKline representatives made sales for purposes of the FLSA, and therefore are exempt outside salesmen within the meaning of the DOL's regulations.

The Court bolstered its conclusion by reasoning that the representatives "bear all of the external indicia of salesmen," insofar as they are hired for their sales experience, are trained to close sales, work away from the office with minimal supervision, and receive incentive compensation. Finally, the Court noted that its holding comports with the apparent purpose of the FLSA's exemption for outside salesmen. In this regard, the Court noted that the representatives, who earned an average of more than $70,000 per year and who worked on their assigned portfolio of drugs between 10 and 20 hours outside of normal business hours, "are hardly the kind of employees that the FLSA was intended to protect." Concluding that the representatives qualify as outside salesmen under the most reasonable interpretation of the DOL's regulations, the Court affirmed the Ninth Circuit's ruling in SmithKline's favor.

Practical Impact

According to Steven F. Pockrass, a shareholder in Ogletree Deakins' Indianapolis office and co-chair of the firm's Wage and Hour Practice Group: "This is a significant victory for employers. Not only did the Court hold that the DOL's interpretation of its outside sales representative regulations in this case was not entitled to deference, but it also held that the DOL's interpretation was wrong."

Pockrass continued: "The Court's decision demonstrates that common sense and fair play need not be thrown by the wayside when interpreting the FLSA. The Court recognized that the plaintiffs were not low-paid employees, but well-compensated individuals, and the industry had engaged in a decades-long practice of classifying employees in these positions as exempt outside salespeople without any challenge by the DOL. It was only after the plaintiffs' bar attacked this practice that the DOL announced its position in amicus briefs. As the Supreme Court noted, giving deference to the DOL's interpretation would have imposed massive liability for conduct that occurred well before that interpretation was announced and would not have provided fair notice."

"Although employers in industries that have not been the targets of DOL enforcement actions or the subjects of DOL opinion letters can take some comfort in this decision, the ruling certainly is not going to shut the door on wage and hour lawsuits by the plaintiffs' bar."

"The decision also is not going to stop the DOL from trying to find ways to challenge employers. For example, we may see the DOL's Wage and Hour Division start issuing FLSA Administrator Interpretations again, as it first began doing in 2010, so that it can make a 'fair notice' argument. The Wage and Hour Division also has targeted several industries for enforcement actions, and this ruling may spur it to take on more targets so that it has a record of contending that a certain practice was unlawful prior to taking a stance in litigation or in amicus briefs."

According to Alfred B. Robinson, Jr., a shareholder in Ogletree Deakins' Washington, D.C. office, co-chair of the firm's Wage and Hour Practice Group, and former acting Administrator of the Wage and Hour Division of the DOL: "This decision is significant not only for the pharmaceutical industry but also for other industries that utilize the outside sales employee exemption in their business models. In its analysis of what constitutes a sale, the Court recognized that the definition attempts 'to accommodate industry-by-industry variations in methods of selling commodities.' The Court viewed this definition as an industry specific standard of sales activities that are tantamount to the sale of a commodity."

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions